Document is current
Any future updates will be listed below
-
Authors
Doman, Jordan L.
Sousa, Alexander A.
Randolph, Peyton B.
Chen, Peter J.
Liu, David R. http://orcid.org/0000-0002-9943-7557
-
Funding
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (U01AI142756)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (RM1HG009490)
U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (R01EB031172)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM118062)
Howard Hughes Medical Institute (Liu investigatorship)
Bill and Melinda Gates Foundation (Liu grant)
- License Information
-
More Information
Article History
Received: 17 February 2022
Accepted: 19 May 2022
First Online: 8 August 2022
Competing interests
: J.L.D., A.A.S., P.B.R., P.J.C. and D.R.L. have filed patent applications on PE technologies and applications. P.J.C. is currently an employee of Prime Medicine. D.R.L. is a consultant and equity holder of Prime Medicine, Beam Therapeutics, Pairwise Plants and Chroma Medicine, companies that use genome editing or genome engineering.
